Add like
Add dislike
Add to saved papers

Comprehensive analysis of aberrantly expressed microRNA profiles reveals potential biomarkers of human lung adenocarcinoma progression.

Oncology Reports 2017 October
Lung adenocarcinoma (LUAD) is a complex disease that poses challenges for diagnosis and treatment. The aim of the present study is to investigate LUAD-specific key microRNAs (miRNAs) from large-scale samples in The Cancer Genome Atlas (TCGA) database. We used an integrative computational method to identify LUAD-specific key miRNAs related to TNM stage and lymphatic metastasis from the TCGA database. Twenty-five LUAD-specific key miRNAs (fold change >2, p<0.05) from the TCGA database were investigated, and 15 were found to be aberrantly expressed with respect to clinical features. Three miRNAs were correlated with overall survival (log-rank p<0.05). Then, 5 miRNAs were randomly selected for verification of expression in 53 LUAD patient tissues using qRT-PCR. Diagnostic value of these above 5 miRNAs was determined by areas under receiver operating characteristic curves (ROC). Finally, the LUAD-related miRNA miR-30a-3p was selected for verification of biologic function in A549 cells. The results of tests for cell proliferation, apoptosis, and target genes suggested that miR-30a-3p decreases cell proliferation and promotes apoptosis through targeting AKT3. Therefore, miR-30a-3p may be a promising biomarker for the early screening of high-risk populations and early diagnosis of LUAD. Our studies provide insights into identifying novel potential biomarkers for diagnosis and prognosis of LUAD.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app